NR602 / NR 602 Midterm Exam (Latest
2025/2026): Primary Care of the Childbearing &
Childrearing Family Practicum – Chamberlain |
Verified Questions & Answers | A+ Graded
Verified Questions & Answers | A+ Graded | 100+ High-Yield Items from Official Banks
This A+ guide compiles 100+ verified questions for the NR602 Midterm Exam (Chamberlain
University, 2025/2026), focusing on primary care for families, including immunizations,
screening, failure to thrive, lead poisoning, newborn assessment, and common
pediatric/adolescent issues.
Section 1: Immunizations & Vaccines (Questions 1-20)
1 What is the recommendation for human papillomavirus (HPV) vaccine? 2 or 3 doses starting
at age 11-12; up to age 26 if not completed Rationale: Prevents cervical/oral cancers; 2 doses
if <15 years, 3 if older (CDC/ACIP 2025; AAP Red Book). NGN SATA: Not annual booster;
catch-up for 13-26 yo.
2 When does anaphylaxis occur after vaccination? Immediately or up to 2 hours later
Rationale: IgE-mediated; epinephrine IM first-line (CDC Vaccine Safety Datalink 2025; GCU
Primary Care Rubric). Case study: Rash/hives cue → Epi 0.01 mg/kg.
3 What could cause anaphylaxis post-vaccine? Egg protein in some vaccines (e.g., influenza)
Rationale: Contraindication if severe allergy; skin test if moderate (AAP 2025; not gelatin/yeast
for all). Differential: Vasovagal vs. true anaphylaxis.
4 Recommended newborn screening? Hearing loss by 1 month; asymmetrical red reflex to
ophthalmology Rationale: Universal EHDI; red reflex for retinoblastoma (AAP Newborn
Screening Guidelines 2025; GCU Assessment). SATA: PKU/metabolic via heel stick.
5 HPV vaccine schedule for adolescents? Dose 1 at 11-12, dose 2 at 6 months Rationale:
Gardasil 9; 2-dose if initiated <15 years (CDC 2025; VFC program). Rationale: Efficacy >90%
vs. HPV 16/18.
6 Contraindication for live vaccines (e.g., MMR)? Immunocompromised child Rationale: Risk
of dissemination; delay if moderate illness (AAP Red Book 2025; GCU Immunization Rubric).
NGN: Cue (chemo) → Prioritize (inactivated alt).
7 DTaP vaccine doses in first year? 3 doses at 2, 4, 6 months Rationale: Primary series; booster
at 15-18 months (CDC Schedule 2025). SATA: Not 4 doses in infancy.
, 8 Rotavirus vaccine contraindication? History of intussusception Rationale: RotaTeq/Rotarix;
screen for GI issues (AAP 2025). Rationale: Rare risk <1/100,000.
9 Influenza vaccine for 6 months-8 years? 2 doses first season, 1 thereafter Rationale: Poor
prior immunity; LAIV or IM (CDC Flu 2025). Differential: Egg allergy (use Flucelvax).
10 Catch-up varicella vaccine for 13+ years? 2 doses 4-8 weeks apart Rationale: MMRV or
VAR; history of disease exempts (AAP 2025; GCU Peds). NGN bow-tie: No history cue → 2
doses.
11 Hepatitis B vaccine birth dose? Within 24 hours for all infants Rationale: Prevents
perinatal transmission; 3-dose series (CDC 2025). SATA: Not optional for low-risk.
12 Meningococcal vaccine for adolescents? MenACWY at 11-12, booster 16 Rationale:
Serogroup protection; MenB optional (ACIP 2025). Rationale: College dorm risk.
13 Tdap booster recommendation? Every 10 years; pregnancy 27-36 weeks Rationale:
Pertussis prevention; adolescent dose 11-12 (CDC 2025; GCU Maternity).
14 Pneumococcal vaccine for high-risk children? PCV13 + PPSV23 series Rationale: Sickle
cell/asthma; shared decision (AAP 2025). Differential: PCV15/20 updates.
15 COVID-19 vaccine for children 6 months+? mRNA series (Pfizer/Moderna), boosters per
CDC Rationale: Omicron variant protection; 2-3 doses initial (ACIP 2025). NGN: Cue
(exposure) → Vaccinate.
16 Polio vaccine schedule? IPV 4 doses at 2, 4, 6-18 months, 4-6 years Rationale: Inactivated;
no OPV in US (CDC 2025). Rationale: Eradication goal.
17 MMR vaccine doses? 1st at 12-15 months, 2nd 4-6 years Rationale: Measles immunity;
catch-up if missed (AAP 2025). SATA: Not <12 months routine.
18 HPV vaccine for males? Same as females, 11-12 start Rationale: Anogenital warts/cancer
prevention (CDC 2025; GCU Adolescent).
19 RSV monoclonal antibody for infants? Nirsevimab for <8 months high-risk Rationale:
Seasonally; bronchiolitis prevention (AAP 2025). Differential: Palivizumab for prematurity.
20 Vaccine storage temperature? 2-8°C (refrigerator) Rationale: VFC guidelines; monitor logs
(CDC 2025; GCU Primary Care).
Section 2: Growth & Development / Failure to Thrive (Questions 21-40)
21 Failure to thrive definition? Inadequate weight gain relative to age Rationale: <5th
percentile or crossing 2 major curves down (AAP 2025; GCU Peds Growth). NGN: Cue (weight
drop) → Assess intake.
2025/2026): Primary Care of the Childbearing &
Childrearing Family Practicum – Chamberlain |
Verified Questions & Answers | A+ Graded
Verified Questions & Answers | A+ Graded | 100+ High-Yield Items from Official Banks
This A+ guide compiles 100+ verified questions for the NR602 Midterm Exam (Chamberlain
University, 2025/2026), focusing on primary care for families, including immunizations,
screening, failure to thrive, lead poisoning, newborn assessment, and common
pediatric/adolescent issues.
Section 1: Immunizations & Vaccines (Questions 1-20)
1 What is the recommendation for human papillomavirus (HPV) vaccine? 2 or 3 doses starting
at age 11-12; up to age 26 if not completed Rationale: Prevents cervical/oral cancers; 2 doses
if <15 years, 3 if older (CDC/ACIP 2025; AAP Red Book). NGN SATA: Not annual booster;
catch-up for 13-26 yo.
2 When does anaphylaxis occur after vaccination? Immediately or up to 2 hours later
Rationale: IgE-mediated; epinephrine IM first-line (CDC Vaccine Safety Datalink 2025; GCU
Primary Care Rubric). Case study: Rash/hives cue → Epi 0.01 mg/kg.
3 What could cause anaphylaxis post-vaccine? Egg protein in some vaccines (e.g., influenza)
Rationale: Contraindication if severe allergy; skin test if moderate (AAP 2025; not gelatin/yeast
for all). Differential: Vasovagal vs. true anaphylaxis.
4 Recommended newborn screening? Hearing loss by 1 month; asymmetrical red reflex to
ophthalmology Rationale: Universal EHDI; red reflex for retinoblastoma (AAP Newborn
Screening Guidelines 2025; GCU Assessment). SATA: PKU/metabolic via heel stick.
5 HPV vaccine schedule for adolescents? Dose 1 at 11-12, dose 2 at 6 months Rationale:
Gardasil 9; 2-dose if initiated <15 years (CDC 2025; VFC program). Rationale: Efficacy >90%
vs. HPV 16/18.
6 Contraindication for live vaccines (e.g., MMR)? Immunocompromised child Rationale: Risk
of dissemination; delay if moderate illness (AAP Red Book 2025; GCU Immunization Rubric).
NGN: Cue (chemo) → Prioritize (inactivated alt).
7 DTaP vaccine doses in first year? 3 doses at 2, 4, 6 months Rationale: Primary series; booster
at 15-18 months (CDC Schedule 2025). SATA: Not 4 doses in infancy.
, 8 Rotavirus vaccine contraindication? History of intussusception Rationale: RotaTeq/Rotarix;
screen for GI issues (AAP 2025). Rationale: Rare risk <1/100,000.
9 Influenza vaccine for 6 months-8 years? 2 doses first season, 1 thereafter Rationale: Poor
prior immunity; LAIV or IM (CDC Flu 2025). Differential: Egg allergy (use Flucelvax).
10 Catch-up varicella vaccine for 13+ years? 2 doses 4-8 weeks apart Rationale: MMRV or
VAR; history of disease exempts (AAP 2025; GCU Peds). NGN bow-tie: No history cue → 2
doses.
11 Hepatitis B vaccine birth dose? Within 24 hours for all infants Rationale: Prevents
perinatal transmission; 3-dose series (CDC 2025). SATA: Not optional for low-risk.
12 Meningococcal vaccine for adolescents? MenACWY at 11-12, booster 16 Rationale:
Serogroup protection; MenB optional (ACIP 2025). Rationale: College dorm risk.
13 Tdap booster recommendation? Every 10 years; pregnancy 27-36 weeks Rationale:
Pertussis prevention; adolescent dose 11-12 (CDC 2025; GCU Maternity).
14 Pneumococcal vaccine for high-risk children? PCV13 + PPSV23 series Rationale: Sickle
cell/asthma; shared decision (AAP 2025). Differential: PCV15/20 updates.
15 COVID-19 vaccine for children 6 months+? mRNA series (Pfizer/Moderna), boosters per
CDC Rationale: Omicron variant protection; 2-3 doses initial (ACIP 2025). NGN: Cue
(exposure) → Vaccinate.
16 Polio vaccine schedule? IPV 4 doses at 2, 4, 6-18 months, 4-6 years Rationale: Inactivated;
no OPV in US (CDC 2025). Rationale: Eradication goal.
17 MMR vaccine doses? 1st at 12-15 months, 2nd 4-6 years Rationale: Measles immunity;
catch-up if missed (AAP 2025). SATA: Not <12 months routine.
18 HPV vaccine for males? Same as females, 11-12 start Rationale: Anogenital warts/cancer
prevention (CDC 2025; GCU Adolescent).
19 RSV monoclonal antibody for infants? Nirsevimab for <8 months high-risk Rationale:
Seasonally; bronchiolitis prevention (AAP 2025). Differential: Palivizumab for prematurity.
20 Vaccine storage temperature? 2-8°C (refrigerator) Rationale: VFC guidelines; monitor logs
(CDC 2025; GCU Primary Care).
Section 2: Growth & Development / Failure to Thrive (Questions 21-40)
21 Failure to thrive definition? Inadequate weight gain relative to age Rationale: <5th
percentile or crossing 2 major curves down (AAP 2025; GCU Peds Growth). NGN: Cue (weight
drop) → Assess intake.
